{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:32:00Z","timestamp":1790890320368,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methadone therapy clinics have been recently introduced in Tanzania, aiming at reducing risk behaviors and infection rates of viral hepatitis and HIV among people who use drugs. The objective of this study was to estimate the prevalence, associated factors and knowledge level of these conditions among people who use drugs attending a methadone clinic in Tanzania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 253 People who using drugs receiving Methadone therapy. Clinical data was retrospectively collected from the medical records and face-to face interviews were conducted to determine the behavioral risk factors and respondents\u2019 knowledge on viral hepatitis and HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An overall seroprevalence of viral hepatitis (either hepatitis B surface antigen or anti-hepatitis C virus) was 6.3%, while that of hepatitis B virus mono infection was 3.5% and anti-hepatitis C antibodies was 3.5%. Seroprevalence of HIV was 12.6%. Viral hepatitis was strongly predicted by advanced age (&gt;\u200935\u2009years) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and staying at Kirumba area (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), and HIV infection was predicted by increased age (&gt;\u200937\u2009years) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and female sex (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Regarding the knowledge of viral hepatitis, majority of the respondents were unaware of the transmission methods and availability of hepatitis B virus vaccines and only 17% were classified as well informed (provided \u22654 correct answers out of 7 questions). Good knowledge was highly predicted by higher education level of the individual (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection rates among people who use drugs are still high and the general knowledge on preventive measures is inadequate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06393-0","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T09:05:38Z","timestamp":1626858338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-9368","authenticated-orcid":false,"given":"Semvua B.","family":"Kilonzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Majinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyasinta","family":"Jaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina M.","family":"Manyiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Kalokola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame","family":"Mtui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elichilia R.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma A.","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stephano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"6393_CR1","volume-title":"Global Hepatitis Report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization: Global Hepatitis Report. 2017. https:\/\/www.who.int\/global hepatitis report. Accessed 24 Oct 2020."},{"issue":"12","key":"6393_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.annepidem.2018.10.009","volume":"28","author":"CR Woodyatt","year":"2018","unstructured":"Woodyatt CR. World AIDS day 2018. Ann Epidemiol. 2018;28(12):829. https:\/\/doi.org\/10.1016\/j.annepidem.2018.10.009.","journal-title":"Ann Epidemiol"},{"key":"6393_CR3","volume-title":"National strategic plan for control of viral hepatitis","author":"Ministry of Health, Community Development, Gender, Health and Children","year":"2018","unstructured":"Ministry of Health, Community Development, Gender, Health and Children. National strategic plan for control of viral hepatitis. 2018. https:\/\/www.moh.go.tz\/national strategic plan for the control of viral hepatitis. Accessed 25 Sept 2020."},{"key":"6393_CR4","volume-title":"Tanzania HIV Impact Survey","author":"National Bureau of Statistics","year":"2019","unstructured":"National Bureau of Statistics. Tanzania HIV Impact Survey. 2019. https:\/\/www.nbs.go.tz\/HIV impact survey. Accessed 19 Oct 2020."},{"key":"6393_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-8294-8","volume":"20","author":"RH Kawambwa","year":"2020","unstructured":"Kawambwa RH, Majigo MV, Mohamed AA, Matee MI. High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania. BMC Public Health. 2020;20:1.","journal-title":"BMC Public Health"},{"issue":"2","key":"6393_CR6","first-page":"128","volume":"5","author":"MJ Dahoma","year":"2006","unstructured":"Dahoma MJ, Salim AA, Abdool R, Othman AA, Makame H, Ali AS, et al. HIV and substance abuse: the dual epidemics challenging Zanzibar. African J Drug Alcohol Stud. 2006;5(2):128.","journal-title":"African J Drug Alcohol Stud"},{"issue":"1","key":"6393_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-019-0346-y","volume":"16","author":"GH Leyna","year":"2019","unstructured":"Leyna GH, Makyao N, Mwijage A, Ramadhan A, Likindikoki S, Mizinduko M, et al. HIV\/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination. Harm Reduct J. 2019;16(1):1.","journal-title":"Harm Reduct J"},{"issue":"1","key":"6393_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-017-4933-0","volume":"17","author":"A Khatib","year":"2017","unstructured":"Khatib A, Matiko E, Khalid F, Welty S, Ali A, Othman A, et al. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health. 2017;17(1):1\u20136.","journal-title":"BMC Public Health"},{"key":"6393_CR9","volume-title":"Consensus estimates on key population size and HV prevalence in Tanzania","author":"National AIDS Control Programme","year":"2014","unstructured":"National AIDS Control Programme. Consensus estimates on key population size and HV prevalence in Tanzania. 2014. https:\/\/www.healthpolicyproject.com\/consensus report. Accessed 01 Oct 2020."},{"issue":"1","key":"6393_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10461-018-2057-x","volume":"22","author":"J Ndayongeje","year":"2018","unstructured":"Ndayongeje J, Msami A, Laurent YI, Mwankemwa S, Makumbuli M, Ngonyani AM, et al. Illicit drug users in the Tanzanian hinterland: population size estimation through key informant-driven hot spot mapping. AIDS Behav. 2018;22(1):4\u20139. https:\/\/doi.org\/10.1007\/s10461-018-2057-x.","journal-title":"AIDS Behav"},{"key":"6393_CR11","volume-title":"National standard operating procedures for management of Opioid use disorders","author":"Ministry of Health, Community Development, Gender, Elderly and Children","year":"2019","unstructured":"Ministry of Health, Community Development, Gender, Elderly and Children. National standard operating procedures for management of Opioid use disorders. 2019. https:\/\/www.moh.go.tz\/national standard operating procedures for management of Opiod use disorders. Accessed 26 Aug 2020."},{"key":"6393_CR12","volume-title":"National comprehensive guidelines on HIV testing services","author":"Ministry of Health, Community Development, Gender, Elderly and Children","year":"2019","unstructured":"Ministry of Health, Community Development, Gender, Elderly and Children. National comprehensive guidelines on HIV testing services. 2019. http:\/\/www.nacp.go.tz\/national comprehensive guidelines on HIV testing services. Accessed 07 Aug 2020."},{"key":"6393_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugpo.2017.05.043","volume":"45","author":"BH Lambdin","year":"2017","unstructured":"Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, et al. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy. 2017;45:64\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.043.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"6393_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/pathogens9060432","volume":"9","author":"R Rashti","year":"2020","unstructured":"Rashti R, Sharafi H, Alavian SM, Moradi Y, Bolbanabad AM, Moradi G. Systematic review and meta-analysis of global prevalence of HBsAg and HIV and HCV antibodies among people who inject drugs and female sex workers. Pathogens. 2020;9(6):432. https:\/\/doi.org\/10.3390\/pathogens9060432.","journal-title":"Pathogens."},{"key":"6393_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1186\/s12879-019-4655-2","volume":"19","author":"CS Baltazar","year":"2019","unstructured":"Baltazar CS, Horth R, Boothe M, Sathane I, Young P, Langa DC, et al. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. BMC Infect Dis. 2019;19:1022.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6393_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1186\/s12889-020-09012-w","volume":"20","author":"CS Baltazar","year":"2020","unstructured":"Baltazar CS, Boothe M, Kellogg T, Ricardo P, Sathane I, Fazito E, et al. Prevalence and risk factors associated with HIV\/hepatitis B and HIV\/hepatitis C co-infections among people who inject drugs in Mozambique. BMC Public Health. 2020;20(1):851. https:\/\/doi.org\/10.1186\/s12889-020-09012-w.","journal-title":"BMC Public Health"},{"issue":"12","key":"6393_CR17","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal. 2017;5(12):e1192\u2013207. https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3.","journal-title":"Lancet Glob Heal"},{"issue":"7","key":"6393_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3109\/10826084.2010.517726","volume":"47","author":"R Noori","year":"2012","unstructured":"Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Mansoori KB. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012;47(7):767\u201373. https:\/\/doi.org\/10.3109\/10826084.2010.517726.","journal-title":"Subst Use Misuse."},{"issue":"6","key":"6393_CR19","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.drugpo.2013.07.007","volume":"24","author":"BX Tran","year":"2013","unstructured":"Tran BX, Nguyen LT. Impact of Methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV\/AIDS. Int J Drug Policy. 2013;24(6):e105\u201310.","journal-title":"Int J Drug Policy"},{"key":"6393_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fpubh.2019.00327","volume":"7","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zou X, Xu Y, Medland N, Deng L, Liu Y, et al. The decade-long Chinese methadone maintenance therapy yields large population and economic benefits for drug users in reducing harm, HIV and HCV disease burden. Front Public Heal. 2019;7:327.","journal-title":"Front Public Heal"},{"key":"6393_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.drugpo.2016.03.005","volume":"30","author":"O Ubuguyu","year":"2016","unstructured":"Ubuguyu O, Tran OC, Bruce RD, Masao F, Nyandindi C, Sabuni N, et al. Improvements in health-related quality of life among methadone maintenance clients in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30:74\u201381. https:\/\/doi.org\/10.1016\/j.drugpo.2016.03.005.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"6393_CR22","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","volume":"102","author":"C Van-Den","year":"2007","unstructured":"Van-Den C, Smit C, Van-Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction. 2007;102(9):1454\u201362. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01912.x.","journal-title":"Addiction."},{"issue":"2","key":"6393_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/OLQ.0000000000000555","volume":"44","author":"EJ Mmbaga","year":"2017","unstructured":"Mmbaga EJ, Moen K, Makyao N, Leshabari M. Prevalence and predictors of human immunodeficiency virus and selected sexually transmitted infections among people who inject drugs in Dar es Salaam, Tanzania. Sex Transm Dis. 2017;44(2):79\u201384. https:\/\/doi.org\/10.1097\/OLQ.0000000000000555.","journal-title":"Sex Transm Dis"},{"issue":"1","key":"6393_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/infdis\/jiz058","volume":"220","author":"J Leung","year":"2019","unstructured":"Leung J, Peacock A, Colledge S, Grebely J, Cunningham EB, Hickman M, et al. A global meta-analysis of the prevalence of HIV, hepatitis C virus, and hepatitis B virus among people who inject drugs - do gender-based differences vary by country-level indicators? J Infect Dis. 2019;220(1):78\u201390. https:\/\/doi.org\/10.1093\/infdis\/jiz058.","journal-title":"J Infect Dis"},{"key":"6393_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.drugpo.2017.05.041","volume":"47","author":"TI Mukherjee","year":"2017","unstructured":"Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle\/syringe programs in Malaysia. Int J Drug Policy. 2017;47:144\u201352. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.041.","journal-title":"Int J Drug Policy"},{"issue":"1\u20132","key":"6393_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/10826080902864894","volume":"45","author":"R Cohen-Moreno","year":"2010","unstructured":"Cohen-Moreno R, Schiff M, Levitt S, Bar-Hamburger R, Strauss S, Neumark Y. Knowledge about hepatitis-C among methadone maintenance treatment patients in Israel. Subst Use Misuse. 2010;45(1\u20132):58\u201376. https:\/\/doi.org\/10.3109\/10826080902864894.","journal-title":"Subst Use Misuse"},{"key":"6393_CR27","volume-title":"National guidelines for comprehensive management of Opioid use disorder","author":"Ministry of Health, Community Development, Gender, Elderly and Children","year":"2019","unstructured":"Ministry of Health, Community Development, Gender, Elderly and Children. National guidelines for comprehensive management of Opioid use disorder. 2019. https:\/\/www.moh.go.tz\/guidelines for comprehensive management of opioid use disorder. Accessed 02 Aug 2020."},{"issue":"1","key":"6393_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12879-017-2893-8","volume":"17","author":"D Aaron","year":"2017","unstructured":"Aaron D, Nagu TJ, Rwegasha J, Komba E. Hepatitis B vaccination coverage among healthcare workers at national hospital in Tanzania: how much? Who and why? BMC Infect Dis. 2017;17(1):786. https:\/\/doi.org\/10.1186\/s12879-017-2893-8.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6393_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12879-018-3376-2","volume":"18","author":"ER Shao","year":"2018","unstructured":"Shao ER, Mboya IB, Gunda DW, Ruhangisa FG, Temu EM, Nkwama ML. Seroprevalence of hepatitis B virus infection and associated factors among healthcare workers in northern Tanzania. BMC Infect Dis. 2018;18(1):474. https:\/\/doi.org\/10.1186\/s12879-018-3376-2.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6393_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12879-015-1129-z","volume":"15","author":"A Mueller","year":"2015","unstructured":"Mueller A, Stoetter L, Kalluvya S, Stich A, Majinge C, Weissbrich B. Prevalence of hepatitis B virus infection among health care workers in a tertiary hospital in Tanzania. BMC Infect Dis. 2015;15(1):386. https:\/\/doi.org\/10.1186\/s12879-015-1129-z.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06393-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T09:10:17Z","timestamp":1626858617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6393"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06393-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-116781\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Joint CUHAS\/BMC Research Ethics and scientific review committee (Reference number CREC\/1399\/2019). Permission to conduct the study was obtained from STRRH authorities. Written consent was obtained from each participant after explaining the study aims.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"699"}}